- Home
- VRTX vs AMT Comparison
VRTX vs AMT Comparison
Compare VRTX & AMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- AMT
- Stock Information
- Founded
- VRTX 1989
- AMT 1995
- Country
- VRTX United States
- AMT United States
- Employees
- VRTX N/A
- AMT N/A
- Industry
- VRTX EDP Services
- AMT Real Estate Investment Trusts
- Sector
- VRTX Technology
- AMT Real Estate
- Exchange
- VRTX Nasdaq
- AMT Nasdaq
- Market Cap
- VRTX 96.6B
- AMT 91.3B
- IPO Year
- VRTX 1991
- AMT 1998
- Fundamental
- Price
- VRTX $410.82
- AMT $186.29
- Analyst Decision
- VRTX Buy
- AMT Buy
- Analyst Count
- VRTX 25
- AMT 16
- Target Price
- VRTX $493.64
- AMT $240.94
- AVG Volume (30 Days)
- VRTX 1.7M
- AMT 3.0M
- Earning Date
- VRTX 11-03-2025
- AMT 10-28-2025
- Dividend Yield
- VRTX N/A
- AMT 3.47%
- EPS Growth
- VRTX N/A
- AMT N/A
- EPS
- VRTX 14.07
- AMT 2.77
- Revenue
- VRTX $11,418,800,000.00
- AMT $10,259,600,000.00
- Revenue This Year
- VRTX $10.90
- AMT $4.81
- Revenue Next Year
- VRTX $9.57
- AMT $4.47
- P/E Ratio
- VRTX $29.16
- AMT $67.49
- Revenue Growth
- VRTX 10.46
- AMT 2.24
- 52 Week Low
- VRTX $362.50
- AMT $172.51
- 52 Week High
- VRTX $519.88
- AMT $234.33
- Technical
- Relative Strength Index (RSI)
- VRTX 61.10
- AMT 32.33
- Support Level
- VRTX $400.74
- AMT $188.88
- Resistance Level
- VRTX $411.91
- AMT $194.50
- Average True Range (ATR)
- VRTX 8.84
- AMT 3.24
- MACD
- VRTX 3.92
- AMT -0.21
- Stochastic Oscillator
- VRTX 97.78
- AMT 19.12
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About AMT American Tower Corporation (REIT)
American Tower owns and operates about 150,000 wireless towers throughout the US, Asia, Latin America, Europe, and Africa. It also owns and/or operates 30 data centers in 11 US markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market generated by the top few mobile carriers. The company operates more than 40,000 towers in the US, which accounted for about half of total revenue in 2024. Outside the US, American Tower operates about 48,000 towers in Latin America (dominated by Brazil), 27,000 towers in Europe, and 32,000 towers in Africa. American Tower operates as a REIT.